The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...

An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.